![]() |
|
|
Vol. 283, Issue 2, 869-875, 1997
Departments of
General Surgery (X.X., H.G., L.B., J.S., J.W.W.,
A.S.-F.C.) and
Immunology/Microbiology (A.S.-F.C.), Rush Presbyterian
St. Luke's Medical Center, Chicago, Illinois
Brequinar sodium (BQR) was originally developed as an antitumor drug
and subsequently as an immunosuppressant for controlling transplant
rejection. It has been widely accepted that the antitumor and
immunosuppressive activities of BQR are dependent on its ability to
inhibit the enzymatic activity of dihydroorotate dehydrogenase, the
fourth enzyme in the de novo pyrimidine synthesis
pathway. Recently, we discovered that BQR has the ability to inhibit
protein tyrosine phosphorylation in anti-CD3-stimulated murine T
lymphocytes and to inhibit the activity of src-related protein tyrosine
kinases, p56lck and p59fyn. We examined the in vivo
activities of BQR in MRL-lpr/lpr mice. We report that
the dose of BQR (10 mg/kg/day) that induced anemia, controlled
lymphadenopathy and inhibited autoantibody production, also selectively
reduced the pyrimidine nucleotide levels in the bone marrow and in the
lymph nodes. Coadministration of uridine (1000 mg/kg/day) with BQR
completely normalized pyrimidine nucleotide levels in the bone marrow
and lymph nodes, and prevented BQR-induced anemia. However,
coadministration of uridine with BQR only partially reversed the
anti-proliferative effects of BQR, and did not antagonize the
inhibitory effect of BQR on autoantibody production. Finally, we report
that BQR markedly reduced protein tyrosine phosphorylation in lymph
nodes of MRL-lpr/lpr mice. These results collectively
suggest that the control of lymphadenopathy and autoantibody production
in MRL-lpr/lpr mice by BQR is only partially dependent
on inhibition of pyrimidine nucleotide synthesis, and suggest a
critical role for in vivo inhibition of protein tyrosine
phosphorylation.